Head and neck cancer trials in France

In France 91 Also abroad 942

91 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseNot yet taking people in France
Tumoral Versus Luminal Microbiome in Head and Neck Squamous Cell Carcinoma
Where
Corbeil-Essonnes
Age
18 years and over
People
120
Run by
Centre Hospitalier Sud Francilien
See details and how to joinNCT07809100
Phase 3Taking people
LYSARI – LYmphocyte-Sparing And Radio-Immunotherapy in Head and neck carcinoma - A multicenter, randomised 2*2 factorial design comparing standard to reduced-target volume radiotherapy with or without all-trans retinoic acid (ATRA) in patients with lateralised oropharyngeal, laryngeal and hypopharyngeal squamous cell carcinoma.
Where
Angers, Besancon Cedex, Lille, Lyon, Nice Cedex 2, Paris, Paris Cedex 20, Reims, Saint-Herblain Cedex, Trévenans, Vandouvre Les Nancy, Villejuif
Age
18 years and over
People
630 worldwide
Run by
Centre Leon Berard
See details and how to join2022-501315-13-00 · EU 2022-501315-13-00
Phase 1Taking people
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Where
Villejuif
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00
Phase 3Taking people
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Where
Amiens, Brest, Caen, Dijon, Lille, Lyon, Marseille, Neuilly-sur-Seine, Paris, Pessac, Rennes, Rouen, Saint-Etienne, Valenciennes, Vandœuvre-lès-Nancy, Villejuif
Age
60 years and over
People
500 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT04892173 · EU 2024-520386-31-00
Phase 1/2Taking people
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Where
Avignon Cedex 9, Lille, Nantes, Paris, Villejuif
Age
18 years and over
People
287 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06385080 · EU 2023-508418-40-00
Phase 1Taking people
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Where
Brest, Grenoble Cedex 9, Lille, Marseille, Rouen Cedex, Villejuif
Age
18 years to 74 years
People
45 worldwide
Run by
Johnson & Johnson Enterprise Innovation Inc.
See details and how to joinNCT07219212 · EU 2025-522914-22-00
Phase 3Taking people
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Where
Avignon Cedex 9, Le Mans, Lille, Marseille, Paris, Rouen Cedex, Saint-Herblain Cedex, Villejuif
Age
18 years and over
People
600 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07276399 · EU 2025-521917-24-00
Phase 1/2Taking people
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Where
Bordeaux, Lyon, Marseille, Montpellier Cedex 5, Nice Cedex 2, Paris, Rouen Cedex, Villejuif
Age
18 years and over
People
560 worldwide
Run by
Genmab
See details and how to joinNCT03526835 · EU 2024-513627-16-01
Phase 2/3Taking people
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Where
Amiens Cedex 1, Bordeaux Cedex, Lille, Lyon Cedex 04, Paris, Rennes Cedex, Saint-Grégoire, Strasbourg, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
650 worldwide
Run by
Bicara Therapeutics
See details and how to joinNCT06788990 · EU 2024-519654-37-00
Phase 2Taking people
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Where
Angers, Dijon, Lyon, Marseille, Paris, Poitiers, Saint-Herblain Cedex
Age
18 years and over
People
750 worldwide
Run by
DualityBio Inc.
See details and how to joinNCT06953089 · EU 2025-523895-22-00
Phase 2/3Taking people
Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
Where
Annecy, Clermont-Ferrand, Lille, Lyon, Metz
Age
18 years and over
People
450 worldwide
Run by
Inhibrx Biosciences, Inc
See details and how to joinNCT06295731
Phase 1/2Taking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Bordeaux, Dijon, Lille, Marseille, Toulouse, Villejuif
Age
18 years and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
No phaseNot yet taking people in France
Determinants of Radiation Dermatitis in Head and Neck Cancer Patients Receiving Preventive Photobiomodulation
Where
Férolles-Attilly
Age
18 years and over
People
150
Run by
Hopital Forcilles
See details and how to joinNCT07899866
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bordeaux, Dijon, Lille, Lyon, Marseille, Nantes, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Besancon Cedex, Bordeaux, Bordeaux Cedex, Dijon, Lyon, Montpellier Cedex 5, Paris, Rennes Cedex, Saint-Herblain Cedex, Toulouse Cedex 9, Villejuif
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 2Taking people
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Where
Clermont-Ferrand, Marseille, Paris
Age
18 years and over
People
120 worldwide
Run by
Regeneron Pharmaceuticals
See details and how to joinNCT06769698 · EU 2024-517620-19-00
No phaseNot yet taking people in France
Bacterial Decolonization to Prevent Severe Radiation Dermatitis in Head and Neck Squamous Cell Carcinoma
Where
Angers, Brest, La Roche-sur-Yon, Le Mans, Lille, Lyon, Saint-Nazaire
Age
18 years and over
People
144
Run by
Institut Cancerologie de l'Ouest
See details and how to joinNCT07888907
Phase 2Taking people
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC
Where
Dijon, Grenoble Cedex 9, Marseille, Poitiers, Rennes Cedex, Rouen Cedex
Age
18 years and over
People
160 worldwide
Run by
Bicara Therapeutics
See details and how to joinNCT07807163 · EU 2026-526741-10-00
Phase 2Taking people
Phase II study of ficerafusp alfa in combination with nivolumab in patients with platinum-refractory head and neck squamous cell carcinoma who progressed within 6 months of multimodality therapy for locally advanced disease.
Where
Amiens Cedex 1, Angers, Avignon, Brest, Caen Cedex 5, Créteil, Grenoble Cedex 9, Guilherand-Granges, Le Mans Cedex 2, Lille, Lorient, Lyon, Marseille, Nice Cedex 2, Nimes Cedex 9, Paris Cedex 20, Reims Cedex, Rouen Cedex, Saint-Herblain Cedex, Saint Nazaire Cedex, Strasbourg, Toulouse Cedex 9, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
121
Run by
Groupe Oncologie Radiotherapie Tete Cou
See details and how to join2025-521437-88-00 · EU 2025-521437-88-00
No phaseTaking people
Oncology, Undernutrition and Sensoriality: Links, Mechanisms and Levers for Action
Where
Dijon
Age
18 years and over
People
306
Run by
Centre Hospitalier Universitaire Dijon
See details and how to joinNCT06600295
Phase 3Taking people
A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
Where
Bordeaux, Dijon, Lyon, Marseille, Montpellier, Paris, Saint-Herblain
Age
18 years and over
People
260 worldwide
Run by
Corbus Pharmaceuticals Inc.
See details and how to joinNCT07768189 · EU 2026-527123-94-00
Phase 2Taking people
Phase II Study of Ficerafusp Alfa in Combination With Nivolumab in Patients With Platinum-refractory Head and Neck Squamous Cell Carcinoma
Where
Villejuif
Age
18 years to 75 years
People
131
Run by
Groupe Oncologie Radiotherapie Tete et Cou
See details and how to joinNCT07529873
Phase 1/2Taking people
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Where
Bordeaux, Clermont-Ferrand, Lyon, Nîmes, Saint-Herblain, Strasbourg, Toulouse, Vandœuvre-lès-Nancy, Villejuif
Age
12 years and over
People
300 worldwide
Run by
PMV Pharmaceuticals, Inc
See details and how to joinNCT04585750
Phase 1Taking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Besancon Cedex, Bordeaux, Caen Cedex 5, Clermont Ferrand Cedex1, Marseille, Nice Cedex 2, Paris, Rennes Cedex, Saint-Herblain, Strasbourg Cedex 2, Vandoeuvre Les Nancy_ Cedex, Villejuif
Age
18 years and over
People
1,394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
Phase 3Taking people
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
Where
Avignon, Bordeaux, Le Mans, Lyon, Nice, Saint-Herblain, Toulouse, Villejuif
Age
18 years to 130 years
People
1,145 worldwide
Run by
AstraZeneca
See details and how to joinNCT06129864